MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2174/0113816128374420250707120128

Медицинская библиотека · Current pharmaceutical design · 2026

Mechanistic Insights into Astragalus Membranaceus for Oral Submucosal Fibrosis: A Network Pharmacology and Experimental Approach.

Zhang Fang, Wu Yonglian, Cheng Chen, Cheng YaHsin, Gao Ruifang

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Oral Submucosal Fibrosis (OSF) is a chronic progressive oral mucosal disease with a tendency to progress to cancer. Astragalus membranaceus (AST) is a traditional Chinese medicine used to invigorate Qi and strengthen the body, with anti-fibrosis properties. However, the effect and mechanism of AST on OSF remain unclear.

OBJECTIVE

This study aims to explore the mechanism of Astragalus membranaceus in OSF using network pharmacology and to validate its effects on oral mucosal fibroblasts through in vitro experiments.

METHODS

Network pharmacology was employed to construct an "AST - ingredient - target - OSF" network and perform Protein-Protein Interaction (PPI) analysis. Molecular docking was used to confirm core interactions between key targets and ingredients, and all results met the criterion of a binding energy of <- -1.2 kcal/mol. In vitro experiments were conducted to assess the cytotoxicity of arecoline (ARE) and Astragalus membranaceus injection (ASI) on Oral Mucosal Fibroblasts (OMF).

RESULTS

Analysis revealed 68 common targets between AST and OSF, and a corresponding PPI network was constructed. KEGG and GO enrichment analyses identified 138 pathways and 178 biological processes associated with these targets. Molecular docking confirmed core interactions between five key targets (EGFR, VEGFA, MAPK3, HRAS, JUN) and other ingredients. In vitro experiments showed that ARE at concentrations of 20-40 μg/ml significantly upregulated ACTA2, EGFR, and VEGFA mRNA expression. ASI treatment at varying concentrations significantly inhibited these increases, with 100 mg/ml ASI downregulating EGFR and VEGFA mRNA, and 300-400 mg/ml ASI reducing ACTA2 expression.

DISCUSSION: Astragalus membranaceus injection engages multiple targets and pathways to counteract OSF, aligning with previous antifibrotic evidence and underscoring the need for further in vivo and clinical validation.

CONCLUSION

Astragalus membranaceus injection may suppress ARE-induced fibrosis by targeting EGFR and VEGFA, supporting its potential therapeutic role in the treatment of OSF.

Для цитирования: Zhang Fang, Wu Yonglian, Cheng Chen, Cheng YaHsin, Gao Ruifang. Mechanistic Insights into Astragalus Membranaceus for Oral Submucosal Fibrosis: A Network Pharmacology and Experimental Approach.. Current pharmaceutical design. 2026. DOI: 10.2174/0113816128374420250707120128.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.